Short-term effects of intravitreal dexamethasone implant (OZURDEX®) on choroidal thickness in patients with naive branch retinal vein occlusion

5Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Purpose: The objective of this study was to evaluate subfoveal choroidal thickness (SFCT) using enhanced depth imaging optical coherence tomography (EDI-OCT) in patients with naïve branch retinal vein occlusion (BRVO) before and after intravitreal dexamethasone implant (Ozurdex®) injection. Methods: Thirty-nine patients with unilateral BRVO and 35 healthy subjects were included in this prospective study. Choroidal thickness was evaluated by EDI-OCT at baseline and 1 month after dexamethasone implant. Results: The mean SFCT measured in 39 patients with BRVO was 299.41 ± 55.86 μm, significantly greater than that in contralateral eyes (283.76 ± 57.44 μm; p=0.009) and control eyes (276.14 ± 39.06 μm; p=0.044). The mean SFCT after the treatment was 279.64 ± 50.96 μm, significantly thinner than that before intravitreal dexamethasone therapy (p=0.004). Conclusions: SFCT in treatment-naive BRVO eyes was significantly greater than that in contralateral eyes and healthy eyes and decreased significantly after intravitreal dexamethasone implantation.

Cite

CITATION STYLE

APA

Arifoglu, H. B., Duru, N., Altunel, O., Baskan, B., Alabay, B., & Atas, M. (2016). Short-term effects of intravitreal dexamethasone implant (OZURDEX®) on choroidal thickness in patients with naive branch retinal vein occlusion. Arquivos Brasileiros de Oftalmologia, 79(4), 243–246. https://doi.org/10.5935/0004-2749.20160069

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free